Regarding cancer stage, the majority of patients in both groups were diagnosed at stage I (80.0% vs. 82.2%), followed by stage II (6.7% vs. 8.9%) and stage III EC (13.3% vs. 8.9%), with no significant association between HOXA5 expression and stage distribution (p = 0.796). This evidence concerns the gene HOXA5 and cancer.